Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
RLYB-116 by Rallybio for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
RLYB-116 is under clinical development by Rallybio and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase...
RLYB-116 by Rallybio for Myasthenia Gravis: Likelihood of Approval
RLYB-116 is under clinical development by Rallybio and currently in Phase I for Myasthenia Gravis. According to GlobalData, Phase I...
Risk adjusted net present value: What is the current valuation of Rallybio's RLYB-116?
RLYB-116 is a fusion protein commercialized by Rallybio, with a leading Phase I program in Paroxysmal Nocturnal Hemoglobinuria. According to...